Why Is SciSparc Stock Skyrocketing On Thursday?

SciSparc Ltd. (NASDAQ: SPRC) stock surged 157% on Thursday following a pre-market announcement that its majority-owned subsidiary NeuroThera Labs Inc. received conditional regulatory approval from the TSX Venture Exchange. The approval clears the path for NeuroThera to acquire a 54% majority stake in CliniQuantum Ltd., an Israeli technology company that develops quantum simulation platforms for clinical trial data analysis. The deal, valued at approximately $9.459 million, aims to improve precision in clinical trial outcomes by identifying patient subpopulations responsive to investigational therapies.

05/28/2026, 12:28 PM • Benzinga

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

SciSparc's majority-owned subsidiary NeuroThera Labs has signed a definitive agreement to acquire approximately 54% of CliniQuantum, a quantum technology company specializing in quantum-based clinical trials. NeuroThera will issue 56.6 million common shares valued at approximately $9.46 million, with potential earn-out payments up to $2.5 million based on patent filings and fundraising milestones. The transaction is expected to close by March 31, 2026.

03/10/2026, 9:28 AM • Benzinga

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

SciSparc's subsidiary NeuroThera Labs has signed a non-binding term sheet to acquire a 55% stake in an Israeli quantum computing bio data analysis company, aiming to leverage quantum computing principles for more efficient clinical data processing and research.

12/02/2025, 9:29 AM • Benzinga

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Ltd. has entered into an agreement to acquire a controlling interest in Miza III Ventures Inc., transferring its advanced clinical stage pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals Inc. The transaction values the target assets at approximately $11.6 million and is expected to close around October 22, 2025.

10/15/2025, 7:05 AM • Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session

Multiple health care stocks experienced significant price movements during Monday's after-market trading session, with some companies seeing notable gains while others experienced declines.

09/29/2025, 5:06 PM • Benzinga

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc's majority-owned subsidiary MitoCareX, a drug discovery company targeting resistant cancers, was approved for acquisition by N2OFF. The transaction involves exchanging MitoCareX shares for N2OFF stock and includes financial support commitments.

09/29/2025, 4:03 PM • Benzinga

SciSparc Stock Shoots Up Over 89% After Hours: What's Going On?

SciSparc's stock surged 89.13% after hours following a court-granted stay in its merger proceedings with AutoMax Motors until September 30, amid ongoing challenges in completing the merger agreement.

09/16/2025, 10:50 PM • Benzinga

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

SciSparc Ltd. announced that shareholders of AutoMax Motors have approved a strategic merger, which will result in SciSparc acquiring 100% of AutoMax's share capital through a reverse merger, expanding into the automotive sector.

08/28/2025, 9:24 AM • Benzinga

Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 50 companies are advancing cannabinoid drug research, exploring potential treatments for mental health disorders, neurodegenerative diseases, and chronic inflammation, with promising clinical trials targeting conditions like Alzheimer's, pain management, and epilepsy.

08/12/2025, 1:00 PM • GlobeNewswire

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

SciSparc Ltd. announced progress on its proposed merger with AutoMax Motors Ltd., with the SEC declaring its Form F-4 registration statement effective. The merger involves SciSparc acquiring 100% of AutoMax's share capital through a reverse merger, with shareholder meetings scheduled in August 2025.

07/30/2025, 4:34 PM • Benzinga

Autism Spectrum Disorder Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 20+ Companies and 22+ Therapies | DelveInsight

A comprehensive report reveals a robust pipeline for Autism Spectrum Disorder (ASD) treatments, with over 20 companies developing 22+ potential therapies, driven by improved diagnostics and increasing public awareness.

06/26/2025, 1:00 PM • GlobeNewswire